Haemonetics Corporation $HAE Position Raised by VIRGINIA RETIREMENT SYSTEMS ET Al

VIRGINIA RETIREMENT SYSTEMS ET Al grew its position in shares of Haemonetics Corporation (NYSE:HAE) by 178.6% in the third quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 11,700 shares of the medical instruments supplier’s stock after acquiring an additional 7,500 shares during the quarter. VIRGINIA RETIREMENT SYSTEMS ET Al’s holdings in Haemonetics were worth $1,232,000 at the end of the most recent reporting period.

Other large investors have also recently bought and sold shares of the company. Fortitude Family Office LLC grew its stake in shares of Haemonetics by 104.5% during the 3rd quarter. Fortitude Family Office LLC now owns 272 shares of the medical instruments supplier’s stock worth $29,000 after acquiring an additional 139 shares in the last quarter. Root Financial Partners LLC bought a new stake in shares of Haemonetics in the third quarter worth $40,000. Kelleher Financial Advisors bought a new stake in shares of Haemonetics in the second quarter worth $38,000. Northwestern Mutual Wealth Management Co. acquired a new position in Haemonetics during the second quarter worth $44,000. Finally, Public Employees Retirement System of Ohio acquired a new position in Haemonetics during the second quarter worth $54,000. Institutional investors and hedge funds own 99.67% of the company’s stock.

Haemonetics Trading Up 5.9%

Shares of NYSE:HAE opened at $127.40 on Thursday. Haemonetics Corporation has a 12-month low of $49.96 and a 12-month high of $128.83. The business has a 50 day moving average of $110.86 and a 200-day moving average of $79.55. The company has a quick ratio of 1.91, a current ratio of 3.08 and a debt-to-equity ratio of 1.40. The stock has a market cap of $5.80 billion, a PE ratio of 62.45, a P/E/G ratio of 2.40 and a beta of 0.63.

Haemonetics (NYSE:HAE) last issued its quarterly earnings data on Thursday, August 6th. The medical instruments supplier reported $1.14 earnings per share for the quarter, topping the consensus estimate of $1.08 by $0.06. The business had revenue of $339.38 million during the quarter, compared to analysts’ expectations of $327.86 million. Haemonetics had a net margin of 7.12% and a return on equity of 27.55%. The business’s revenue was up 5.5% on a year-over-year basis. During the same quarter in the previous year, the company earned $1.10 EPS. As a group, equities research analysts forecast that Haemonetics Corporation will post 5.29 earnings per share for the current year.

Analyst Ratings Changes

A number of research firms recently weighed in on HAE. BTIG Research raised their target price on shares of Haemonetics from $110.00 to $130.00 and gave the company a “buy” rating in a research report on Thursday, October 8th. Robert W. Baird boosted their price target on shares of Haemonetics from $96.00 to $119.00 and gave the stock an “outperform” rating in a research report on Friday, August 21st. Mizuho boosted their price target on shares of Haemonetics from $95.00 to $140.00 and gave the stock an “outperform” rating in a research report on Friday, October 9th. Wall Street Zen upgraded shares of Haemonetics from a “buy” rating to a “strong-buy” rating in a research note on Saturday, August 8th. Finally, Barrington Research raised their price objective on Haemonetics from $118.00 to $140.00 and gave the company an “outperform” rating in a report on Friday, October 9th. One equities research analyst has rated the stock with a Strong Buy rating, six have assigned a Buy rating and four have assigned a Hold rating to the company. Based on data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $110.00.

Haemonetics Profile

Haemonetics Corporation (NYSE: HAE) is a healthcare technology company that develops and supplies products and services for blood and plasma collection, processing, and management. Its solutions are used by blood and plasma collection organizations, hospitals, and other healthcare providers to support the efficient handling of blood components and improve patient care.

The company’s offerings include automated plasma and blood-component collection systems, disposable collection sets, blood-processing equipment, and software designed to manage collection and transfusion-related operations.